Navigation Links
ARIUS to present at Chinese Global Financial Forum
Date:10/19/2007

TORONTO, Oct. 19 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that David Young, MD, President and Chief Executive Officer of ARIUS, will speak at the Chinese Global Financial Forum. Dr. Young will present on Saturday October 20th at 3:25 p.m. and will be available prior to and following his presentation at booth #706. The conference is being held at the Hilton Suites Toronto/Markham Conference Centre & Spa. Dr. Young will provide an overview of ARIUS' business and will update the audience on milestones for the Company's lad programs in cancer.

About ARIUS

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 400 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit http://www.ariusresearch.com

Forward-Looking Statements

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results expressed or implied by such statements include, but are not limited to: early stage of development; technology and product development; dependence on and management of current and future corporate collaborations; future capital needs; uncertainty of additional funding; no assurance of market acceptance; dependence on proprietary technology and uncertainty of patent protection; intense competition; manufacturing and market uncertainties; and government regulation. These and other factors are described in detail in ARIUS' Annual Report, forthcoming news releases and other filings with Canadian securities regulatory authorities available at http://www.sedar.com. Forward-looking statements are based on our current expectations and ARIUS is not obligated to update such information to reflect later events or developments.

The TSX has not reviewed and does not accept responsibility for the

adequacy or accuracy of this statement.


'/>"/>
SOURCE ARIUS Research Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Streptococcus salivarius
2. Streptococcus salivarius
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... ... company has acquired the worldwide rights to SQuEEZ heart function analysis software, and ... The U.S. Patent application was filed April 10, 2014 and uses high resolution ...
(Date:7/26/2017)... ... July 25, 2017 , ... ... and software solutions that enable short-run digital printing, is proud to announce that ... its free GHS Wizard online software available at avery.com/GHS . The products ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... ... variety of complex problems we face every day. This unique capability combines ... agronomists, geologists, chemists, and manufacturers to deliver unprecedented datasets for chemical analysis, quality ...
(Date:7/25/2017)... , ... July 25, 2017 , ... Fiberstar, Inc ... and beverage industry, offers Citri-Fi® 125. This natural citrus fiber is used to improve ... extend real tomato in sauces, condiments and spreads. Today, more than ever, consumers connect ...
Breaking Biology Technology:
(Date:3/30/2017)... -- On April 6-7, 2017, Sequencing.com will host the world,s ... at Microsoft,s headquarters in Redmond, Washington ... health and wellness apps that provide a unique, personalized ... is the first hackathon for personal genomics and the ... the genomics, tech and health industries are sending teams ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/24/2017)... Controller General of Immigration from Maldives Mr. Mohamed Anwar and ... international IAIR Award for the most innovative high security ePassport and eGates  ... ... Maldives Immigration Controller General, Mr. Mohamed Anwar ... right) have received the IAIR award for the "Most innovative high security ...
Breaking Biology News(10 mins):